NASDAQ:EOLS Evolus Q2 2025 Earnings Report $9.53 -0.12 (-1.24%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$9.54 +0.01 (+0.10%) As of 07/25/2025 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Evolus EPS ResultsActual EPSN/AConsensus EPS -$0.09Beat/MissN/AOne Year Ago EPSN/AEvolus Revenue ResultsActual RevenueN/AExpected Revenue$82.18 millionBeat/MissN/AYoY Revenue GrowthN/AEvolus Announcement DetailsQuarterQ2 2025Date8/5/2025TimeAfter Market ClosesConference Call DateTuesday, August 5, 2025Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Evolus Earnings HeadlinesEvolus to Report Second Quarter Financial Results on August 5, 2025July 22, 2025 | businesswire.comEvolus - A Slightly Risky Buy Ahead Of Q2 EarningsJuly 21, 2025 | seekingalpha.comTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that you don't want to take with your retirement savings.July 26 at 2:00 AM | Create New Advertiser (Ad)Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 11, 2025 | businesswire.comEvolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in FranceJuly 9, 2025 | businesswire.comEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 13, 2025 | businesswire.comSee More Evolus Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Evolus? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Evolus and other key companies, straight to your email. Email Address About EvolusEvolus (NASDAQ:EOLS), a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.View Evolus ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Is Former Dividend Aristocrat AT&T a Buy After Q2 Earnings?Why Freeport-McMoRan Stock May Hit a New High After Earnings BeatMicrosoft’s AI Bet Faces a Major Test This Earnings SeasonAmazon Stock Rally Hits New Highs: Buy Into Earnings?TSLA Earnings Week: Can Tesla Break Through $350?Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your Portfolio Upcoming Earnings Cadence Design Systems (7/28/2025)Enterprise Products Partners (7/28/2025)Welltower (7/28/2025)Waste Management (7/28/2025)Starbucks (7/29/2025)PayPal (7/29/2025)AstraZeneca (7/29/2025)Mondelez International (7/29/2025)Booking (7/29/2025)America Movil (7/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
